GÉTICA 2021

21 [ F I T C á n c e r - 7 ] index of biopharmaceuticals, with a special fo- cus on pro-inflammatory cytokines. I will also show how antibody-cytokine fusions, capable of selective homing at the tumor site and fea- turing interleukin-2, interleukin-12 or tumor ne- crosis factor as payload, can be potently active against different types of tumors. RECOMMENDED REFERENCE 1. Neri D.Antibody-cytokine fusions: versatile products for the modulation of anticancer immunity. Cancer Immu- nol Res 2018;7:348-54. Dario Neri ETH Zurich (Swiss Federal Institute of Technology in Zurich). Zurich, Switzerland T here is a trend in “arming” antibodies with bioactive payloads for the therapy of cancer and of chronic inflammatory conditions. Popular payloads include drugs, radionuclides, cytokines, bi-specific antibod- ies and CAR-Ts. In this lecture, I will show how we have validated the targeting ability of anti- bodies and of small molecules, first in mouse models and later in patients, as a pre-requisite for the development of targeted therapeutics. I will also discuss the impact that targeting can have on the improvement of the therapeutic Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer